PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

Andrea Sartore-Bianchi, Miriam Martini, Francesca Molinari, Silvio Veronese, Michele Nichelatti, Salvatore Artale, Federica Di Nicolantonio, Piercarlo Saletti, Sara De Dosso, Luca Mazzucchelli, Milo Frattini, Salvatore Siena, Alberto Bardelli

Research output: Contribution to journalArticle

577 Citations (Scopus)

Abstract

The monoclonal antibodies (moAb) panitumumab and cetux-imab target the epidermal growth factor receptor (EGFR) and have proven valuable for the treatment of metastatic colorectal cancer (mCRC). EGFR-mediated signaling involves two main intracellular cascades: on one side KRAS activates BRAF, which in turn triggers the mitogen-activated pro-tein kinases. On the other, membrane localization of the lipid kinase PIK3CA counteracts FTEN and promotes AKTl phos-phorylation, thereby activating a parallel intracellular axis. Constitutive activation of KRAS bypasses the corresponding signaling cascade and, accordingly, patients with mCRC bearing KRAS mutations are clinically resistant to therapy with panitumumab or cetuximab. We hypothesized that mutations activating PIK3CA could also preclude responsive-ness to EGFR-targeted moAbs through a similar mechanism. Here, we present the mutational analysis of PIK3CA and KRAS and evaluation of the PTEN protein status in a cohort of 110 patients with mCRC treated with anti-EGFR moAbs. We observed 15 (13.6%) PIK3CA and 32 (29.0%) KRAS mutations. PIK3CA mutations were significantly associated with clinical resistance to panitumumab or cetuximab; none of the mutated patients achieved objective response (P = 0.038). When only KRAS wild-type tumors were analyzed, the statistical correlation was stronger (P = 0.016). Patients with PIK3CA mutations displayed a worse clinical outcome also in terms of progression-free survival (P = 0.035). Our data indicate that PIK3CA mutations can independently hamper the therapeutic response to panitumumab or cetuximab in mCRC. When the molecular status of the PIK3CA/PTEN and KRAS pathways are concomitantly ascertained, up to 70% of mCRC patients unlikely to respond to EGFR moAbs can be identified.

Original languageEnglish
Pages (from-to)1851-1857
Number of pages7
JournalCancer Research
Volume69
Issue number5
DOIs
Publication statusPublished - Mar 1 2009

Fingerprint

Epidermal Growth Factor Receptor
Colorectal Neoplasms
Monoclonal Antibodies
Mutation
Phosphotransferases
PTEN Phosphohydrolase
Membrane Lipids
Mitogens
Disease-Free Survival
Therapeutics
panitumumab
Cetuximab
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. / Sartore-Bianchi, Andrea; Martini, Miriam; Molinari, Francesca; Veronese, Silvio; Nichelatti, Michele; Artale, Salvatore; Di Nicolantonio, Federica; Saletti, Piercarlo; De Dosso, Sara; Mazzucchelli, Luca; Frattini, Milo; Siena, Salvatore; Bardelli, Alberto.

In: Cancer Research, Vol. 69, No. 5, 01.03.2009, p. 1851-1857.

Research output: Contribution to journalArticle

Sartore-Bianchi, A, Martini, M, Molinari, F, Veronese, S, Nichelatti, M, Artale, S, Di Nicolantonio, F, Saletti, P, De Dosso, S, Mazzucchelli, L, Frattini, M, Siena, S & Bardelli, A 2009, 'PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies', Cancer Research, vol. 69, no. 5, pp. 1851-1857. https://doi.org/10.1158/0008-5472.CAN-08-2466
Sartore-Bianchi, Andrea ; Martini, Miriam ; Molinari, Francesca ; Veronese, Silvio ; Nichelatti, Michele ; Artale, Salvatore ; Di Nicolantonio, Federica ; Saletti, Piercarlo ; De Dosso, Sara ; Mazzucchelli, Luca ; Frattini, Milo ; Siena, Salvatore ; Bardelli, Alberto. / PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. In: Cancer Research. 2009 ; Vol. 69, No. 5. pp. 1851-1857.
@article{3beca3fb152a4ba5855a6a1ce8d1ef47,
title = "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies",
abstract = "The monoclonal antibodies (moAb) panitumumab and cetux-imab target the epidermal growth factor receptor (EGFR) and have proven valuable for the treatment of metastatic colorectal cancer (mCRC). EGFR-mediated signaling involves two main intracellular cascades: on one side KRAS activates BRAF, which in turn triggers the mitogen-activated pro-tein kinases. On the other, membrane localization of the lipid kinase PIK3CA counteracts FTEN and promotes AKTl phos-phorylation, thereby activating a parallel intracellular axis. Constitutive activation of KRAS bypasses the corresponding signaling cascade and, accordingly, patients with mCRC bearing KRAS mutations are clinically resistant to therapy with panitumumab or cetuximab. We hypothesized that mutations activating PIK3CA could also preclude responsive-ness to EGFR-targeted moAbs through a similar mechanism. Here, we present the mutational analysis of PIK3CA and KRAS and evaluation of the PTEN protein status in a cohort of 110 patients with mCRC treated with anti-EGFR moAbs. We observed 15 (13.6{\%}) PIK3CA and 32 (29.0{\%}) KRAS mutations. PIK3CA mutations were significantly associated with clinical resistance to panitumumab or cetuximab; none of the mutated patients achieved objective response (P = 0.038). When only KRAS wild-type tumors were analyzed, the statistical correlation was stronger (P = 0.016). Patients with PIK3CA mutations displayed a worse clinical outcome also in terms of progression-free survival (P = 0.035). Our data indicate that PIK3CA mutations can independently hamper the therapeutic response to panitumumab or cetuximab in mCRC. When the molecular status of the PIK3CA/PTEN and KRAS pathways are concomitantly ascertained, up to 70{\%} of mCRC patients unlikely to respond to EGFR moAbs can be identified.",
author = "Andrea Sartore-Bianchi and Miriam Martini and Francesca Molinari and Silvio Veronese and Michele Nichelatti and Salvatore Artale and {Di Nicolantonio}, Federica and Piercarlo Saletti and {De Dosso}, Sara and Luca Mazzucchelli and Milo Frattini and Salvatore Siena and Alberto Bardelli",
year = "2009",
month = "3",
day = "1",
doi = "10.1158/0008-5472.CAN-08-2466",
language = "English",
volume = "69",
pages = "1851--1857",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

AU - Sartore-Bianchi, Andrea

AU - Martini, Miriam

AU - Molinari, Francesca

AU - Veronese, Silvio

AU - Nichelatti, Michele

AU - Artale, Salvatore

AU - Di Nicolantonio, Federica

AU - Saletti, Piercarlo

AU - De Dosso, Sara

AU - Mazzucchelli, Luca

AU - Frattini, Milo

AU - Siena, Salvatore

AU - Bardelli, Alberto

PY - 2009/3/1

Y1 - 2009/3/1

N2 - The monoclonal antibodies (moAb) panitumumab and cetux-imab target the epidermal growth factor receptor (EGFR) and have proven valuable for the treatment of metastatic colorectal cancer (mCRC). EGFR-mediated signaling involves two main intracellular cascades: on one side KRAS activates BRAF, which in turn triggers the mitogen-activated pro-tein kinases. On the other, membrane localization of the lipid kinase PIK3CA counteracts FTEN and promotes AKTl phos-phorylation, thereby activating a parallel intracellular axis. Constitutive activation of KRAS bypasses the corresponding signaling cascade and, accordingly, patients with mCRC bearing KRAS mutations are clinically resistant to therapy with panitumumab or cetuximab. We hypothesized that mutations activating PIK3CA could also preclude responsive-ness to EGFR-targeted moAbs through a similar mechanism. Here, we present the mutational analysis of PIK3CA and KRAS and evaluation of the PTEN protein status in a cohort of 110 patients with mCRC treated with anti-EGFR moAbs. We observed 15 (13.6%) PIK3CA and 32 (29.0%) KRAS mutations. PIK3CA mutations were significantly associated with clinical resistance to panitumumab or cetuximab; none of the mutated patients achieved objective response (P = 0.038). When only KRAS wild-type tumors were analyzed, the statistical correlation was stronger (P = 0.016). Patients with PIK3CA mutations displayed a worse clinical outcome also in terms of progression-free survival (P = 0.035). Our data indicate that PIK3CA mutations can independently hamper the therapeutic response to panitumumab or cetuximab in mCRC. When the molecular status of the PIK3CA/PTEN and KRAS pathways are concomitantly ascertained, up to 70% of mCRC patients unlikely to respond to EGFR moAbs can be identified.

AB - The monoclonal antibodies (moAb) panitumumab and cetux-imab target the epidermal growth factor receptor (EGFR) and have proven valuable for the treatment of metastatic colorectal cancer (mCRC). EGFR-mediated signaling involves two main intracellular cascades: on one side KRAS activates BRAF, which in turn triggers the mitogen-activated pro-tein kinases. On the other, membrane localization of the lipid kinase PIK3CA counteracts FTEN and promotes AKTl phos-phorylation, thereby activating a parallel intracellular axis. Constitutive activation of KRAS bypasses the corresponding signaling cascade and, accordingly, patients with mCRC bearing KRAS mutations are clinically resistant to therapy with panitumumab or cetuximab. We hypothesized that mutations activating PIK3CA could also preclude responsive-ness to EGFR-targeted moAbs through a similar mechanism. Here, we present the mutational analysis of PIK3CA and KRAS and evaluation of the PTEN protein status in a cohort of 110 patients with mCRC treated with anti-EGFR moAbs. We observed 15 (13.6%) PIK3CA and 32 (29.0%) KRAS mutations. PIK3CA mutations were significantly associated with clinical resistance to panitumumab or cetuximab; none of the mutated patients achieved objective response (P = 0.038). When only KRAS wild-type tumors were analyzed, the statistical correlation was stronger (P = 0.016). Patients with PIK3CA mutations displayed a worse clinical outcome also in terms of progression-free survival (P = 0.035). Our data indicate that PIK3CA mutations can independently hamper the therapeutic response to panitumumab or cetuximab in mCRC. When the molecular status of the PIK3CA/PTEN and KRAS pathways are concomitantly ascertained, up to 70% of mCRC patients unlikely to respond to EGFR moAbs can be identified.

UR - http://www.scopus.com/inward/record.url?scp=62449302407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62449302407&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-2466

DO - 10.1158/0008-5472.CAN-08-2466

M3 - Article

VL - 69

SP - 1851

EP - 1857

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 5

ER -